ZENTALIS PHARMACEUTICALS INC (ZNTL) Stock Analyst Earnings Estimates
NASDAQ:ZNTL - Nasdaq - US98943L1070 - Common Stock - Currency: USD
Full estimates are only available for subscribed users, you can see which data is available below.
Subscribed users also see more surprise data, now it is restricted to 4 quarters.
Examples of complete estimate data are available for MSFT and AAPL.
Registered users have access to more data. Please register or login for additional estimates and surprises .
| 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 67.425M | -100.00% | 9.947M | 66.992M 573.49% | 179.54M 168.00% | 308.74M 71.96% | 491.34M 59.14% | 668.99M 36.16% | ||||
| EBITDA YoY % growth | -225.86M -9.01% | -247.552M -9.60% | -186.169M 24.80% | -267.353M -43.61% | -288.044M -7.74% | -289.005M -0.33% | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -227.29M -9.41% | -248.941M -9.53% | -187.458M 24.70% | -180.566M 3.68% | -187.438M -3.81% | -195.219M -4.15% | -152.282M 21.99% | -58.124M 61.83% | 43.133M 174.21% | 156.54M 262.92% | 258.52M 65.15% | |
| Operating Margin | N/A | N/A | -278.02% | N/A | N/A | -1,962.59% | -227.31% | -32.37% | 13.97% | 31.86% | 38.64% | |
| EPS YoY % growth | -4.53 8.30% | -4.64 -2.43% | -2.28 50.86% | -2.30 -0.77% | -2.06 10.16% | -1.94 6.26% | -1.40 27.68% | -0.35 74.67% | 0.27 175.77% | 0.77 184.85% | 1.43 86.67% |
All data in USD
| Q2 / 25 | Q3 / 25 | Q4 / 25 | Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.54 56.20% | -0.55 2.33% | -0.56 8.98% | -0.64 -14.14% | -0.74 -37.09% | -0.74 -36.13% | -0.86 -51.83% |
| Revenue Q2Q % growth | -100.00% | N/A | N/A | N/A | |||
| EBITDA Q2Q % growth | -34.486M 46.53% | -37.822M 25.05% | -38.199M 14.78% | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -40.217M 38.27% | -40.395M 21.46% | -40.897M 11.31% | -44.115M -20.29% | N/A | N/A | N/A |
All data in USD
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q1 2025 Q2Q % growth | -0.56 -500.00% | -0.65 | 0.09 | 13.92% |
| Q4 2024 Q2Q % growth | -0.62 33.33% | -0.72 | 0.10 | 13.88% |
| Q3 2024 Q2Q % growth | -0.56 29.11% | -0.93 | 0.37 | 39.67% |
| Q2 2024 Q2Q % growth | -1.24 32.97% | -0.86 | -0.38 | -44.57% |
| Q1 2024 Q2Q % growth | 0.14 113.08% | -0.78 | 0.92 | 117.90% |
| Q4 2023 Q2Q % growth | -0.93 -1.09% | -0.93 | 0.00 | 0.45% |
| Q3 2023 Q2Q % growth | -0.79 17.71% | -0.93 | 0.14 | 15.05% |
| Q2 2023 Q2Q % growth | -1.85 -38.06% | -1.06 | -0.79 | -74.82% |
| Q1 2023 Q2Q % growth | -1.07 18.32% | -1.04 | -0.03 | -2.90% |
| Q4 2022 Q2Q % growth | -0.92 17.12% | -1.08 | 0.16 | 14.92% |
| Q3 2022 Q2Q % growth | -0.96 23.20% | -1.19 | 0.23 | 19.48% |
| Q2 2022 Q2Q % growth | -1.34 | -1.21 | -0.13 | -10.81% |
| Q1 2022 Q2Q % growth | -1.31 -5.65% | -1.24 | -0.07 | -5.70% |
| Q4 2021 Q2Q % growth | -1.11 -9.90% | -1.52 | 0.41 | 27.21% |
| Q3 2021 Q2Q % growth | -1.25 -37.36% | -1.34 | 0.09 | 6.45% |
| Q2 2021 Q2Q % growth | -1.34 -71.79% | -1.20 | -0.14 | -12.12% |
| Q1 2021 Q2Q % growth | -1.24 56.94% | -0.99 | -0.25 | -25.59% |
| Q4 2020 Q2Q % growth | -1.01 | -0.97 | -0.04 | -3.79% |
| Q3 2020 Q2Q % growth | -0.91 | -0.82 | -0.09 | -10.60% |
| Q2 2020 Q2Q % growth | -0.78 | -0.51 | -0.27 | -51.93% |
| Q1 2020 Q2Q % growth | -2.88 | -0.71 | -2.17 | -303.36% |
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q1 2025 Q2Q % growth | -100.00% | % | ||
| Q1 2024 Q2Q % growth | 40.56M | 13.388M | 27.172M | 202.96% |
| Q1 2020 Q2Q % growth | 102K | -102K | -100.00% |
| Next Q (1 month) | Next Q (3 month) | Next Year (1 month) | Next Year (3 month) | |
|---|---|---|---|---|
| EPS | 0% | 12.99% | 2.33% | 2.91% |
| Revenue | N/A | N/A | N/A | N/A |